Apar Ganti, MD, University of Nebraska Medical Center

Articles by Apar Ganti, MD, University of Nebraska Medical Center

Q & A and Final Thoughts

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Unmet Needs and Challenges in Treating R/R SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Role of Newer Agents in the Treatment & Patient Selection

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Use of I/O Regimen in Relapsed/Refractory SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Advice on Toxicity Management for SCLC Therapy

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Personal Approach in Treatment Compared to Clinical Trials

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Recent Progress in the Treatment of SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Introduction and Identifying Predictive Biomarkers

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Latest Updated Articles

Role of Newer Agents in the Treatment & Patient Selection
August 20th 2020
Advice on Toxicity Management for SCLC Therapy
August 20th 2020
$Data on FDA Approved Therapy for Relapsed/Refractory SCLC$
Data on FDA Approved Therapy for Relapsed/Refractory SCLC
August 20th 2020
Q & A and Final Thoughts
August 20th 2020
Recent Progress in the Treatment of SCLC
August 20th 2020
$Use of I/O Regimen in Relapsed/Refractory SCLC$
Use of I/O Regimen in Relapsed/Refractory SCLC
August 20th 2020

Trending on OncLive

FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC

ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care

Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD

Dr Borate on Efficacy Data for Shorter Venetoclax-Plus-Azacitidine Dosing in AML